Table 2 Laboratory results and medications received by patients suffering from psoriasis-related enthesitis and those without enthesitis
From: Burden of enthesitis on the quality of life and work productivity in psoriatic arthritis patients
Variables | Total PSA (n = 88) | Patients with enthesitis (n = 44) | Patients without enthesitis (n = 44) | Test | p-value | ||
|---|---|---|---|---|---|---|---|
DAPSA | |||||||
(mean ± SD) | 16.17 ± 6.91 | 19.82 ± 6.17 | 12.52 ± 5.59 | −4.979 | < 0.001* | ||
Median (IQR) | 16 (12–22) | 20 (16–24) | 12 (10–16) | ||||
PASI | |||||||
(mean ± SD) | 12.74 ± 10.22 | 13.82 ± 10.28 | 11.66 ± 10.15 | −1.914 | 0.056 | ||
Median (IQR) | 10 (6–16) | 10 (8–16) | 8 (5–14) | ||||
PSAID 12 | −8.228 | < 0.001* | |||||
(mean ± SD) | 4.63 ± 3.42 | 7.79 ± 1.69 | 1.45 ± 0.5 | ||||
Median (IQR) | 3.5 (1–8) | 8 (6–9) | 1 (1–2) | ||||
SPARCC index | −8.686 | < 0.001* | |||||
(mean ± SD) | 3.73 ± 3.99 | 7.45 ± 1.93 | 0 | ||||
Median (IQR) | 1.5 (0–8) | 8 (6–8) | |||||
Acute phase reactant | ESR | 30.05 ± 7.96 | 29.36 ± 6.22 | 30.73 ± 9.42 | −0.802 | 0.425 | |
CRP | −1.852 | 0.064 | |||||
Median (IQR) | 8.72 ± 12.17 5.2 (3.9–8.2) | 11.37 ± 16.35 7.6 (4.2–8.2) | 6.07 ± 4.23 5.2 (2.8–7.6) | ||||
NSJ | 2.6 ± 1.08 | 2.43 ± 0.87 | 2.79 ± 1.2 | −1.58 | 0.117 | ||
NTJ | 13.92 ± 4.3 | 14.54 ± 4.12 | 13.29 ± 4.61 | 1.33 | 0.184 | ||
Current medications, n (%) | NSAIDs | 70 (79.5%) | 44 (100%) | 26 (59.1%) | 22.629 | < 0.001* | |
Corticosteroids | 6 (6.8%) | 4 (9.1%) | 2 (4.5%) | 0.715 | 0.398 | ||
c-DMARDs | MTX | 18 (20.5%) | 7 (15.9%) | 11 (25%) | 1.117 | 0.290 | |
SSZ | 3 (3.4%) | 3 (6.8%) | 0 | 3.106 | 0.078 | ||
Biological | Anti-TNF | 25 (28.4%) | 14 (31.8%) | 11 (25%) | 0.503 | 0.478 | |
Anti-IL-17 | 40 (45.5%) | 23 (52.3%) | 17 (38.6%) | 1.650 | 0.199 | ||